
Results from a phase 3 study and post-hoc analysis highlight the use of galcanezumab-gnlm (Emgality, Eli Lilly) for the treatment of episodic cluster headache and migraine.

Results from a phase 3 study and post-hoc analysis highlight the use of galcanezumab-gnlm (Emgality, Eli Lilly) for the treatment of episodic cluster headache and migraine.

The updated labeling will strengthen warnings for mental health adverse effects and risks related to hypoglycemia.

Top news of the day from across the health care landscape.

New research identified predictors of long-term survival and health-related quality of life in patients with newly diagnosed multiple myeloma.

Pharmaceutical manufacturers depend on hubs to act as connectors between various stakeholders across the specialty drug prescribing process.

The PALOMA-3 trial evaluated palbociclib (Ibrance) in combination with fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.

The American Journal of Medicine has published a new article that describes the reemergence of neurosyphilis and identifies HIV coinfection in individuals in Western countries as a key risk factor.

A new, inexpensive diagnostic test can help identify patients who require immediate treatment for hepatitis B virus across Africa.

Top news of the day from across the health care landscape.

Multiple sclerosis risk increased significantly in individuals with occupational exposure to organic solvents.

Luis Torres, MBA, Vice President, Managed Care, BioPlus Specialty Pharmacy, speaks about why data is a crucial component of choosing a specialty pharmacy.

Researchers have developed a laser-sonic scanner with the ability to detect tumors in as little as 15 seconds.

New study results indicate that an experimental mosaic HIV vaccine may have the potential to protect against a wide-range of global HIV strains.

Top news of the day from across the health care landscape.

Study suggests that super receptors on immune cells can eliminate HIV among genetically diverse patients.

New research suggests psychiatric diseases that affect a patient’s ability to appropriately respond to stimuli may be triggered by the misplacement of an enzyme in the pathway within neurons.

A look at last week's top stories in the world of pharmacy.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

IncobotulinumtoxinA is the first and only neurotoxin approved for this indication in the United States.

Using a DNA test to identify genetic variants in men that increase the likelihood of prostate cancer may help guide interventions for those at high risk and improve disease prevention.

Two recent studies examined the different effects and aspects of progressive multiple sclerosis.

Leticia Shea, PharmD, BCACP, who is an associate professor of pharmacy at Regis University, advises how pharmacists should approach counseling patients who are using medical cannabis.

Top news of the day from across the health care landscape.

In this video, Gordon Vanscoy, PharmD, MBA, explains how policy changes and science have allowed orphan drugs to enter the specialty pharmacy market and create hope for patients.

Using real-time symptom reports, a well-trained classification algorithm can detect lymphedema more accurately than current clinical methods.

Leticia Shea, PharmD, BCACP, who is an associate professor of pharmacy at Regis University, discusses why keeping up to date on the latest medical cannabis laws and research is important for guiding patients.

Atezolizumab (Tecentriq, Roche) plus chemotherapy nab-paclitaxel (Abraxane) met its co-primary endpoint of progression-free survival in patients with metastatic triple-negative breast cancer.

Between 33% and 38% of youth living with HIV use tobacco.

Top news of the day from across the health care landscape.